Authors
Elizabeth A Raetz, Paola Rebora, Valentino Conter, Martin Schrappe, Meenakshi Devidas, Gabriele Escherich, Chihaya Imai, Barbara De Moerloose, Kjeld Schmiegelow, Melissa A Burns, Sarah Elitzur, Rob Pieters, Andishe Attarbaschi, Allen Yeoh, Ching-Hon Pui, Jan Stary, Gunnar Cario, Nicole Bodmer, Anthony V Moorman, Barbara Buldini, Ajay Vora, Maria Grazia Valsecchi
Publication date
2023/11/10
Journal
Journal of Clinical Oncology
Volume
41
Issue
32
Pages
5025-5034
Publisher
Wolters Kluwer Health
Description
PURPOSE
Historically, patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission at the end of induction (EOI) have had poor long-term survival. The goal of this study was to examine the efficacy of contemporary therapy, including allogeneic hematopoietic stem cell transplantation (HSCT) in first remission (CR1).
METHODS
Induction failure (IF) was defined as the persistence of at least 5% bone marrow (BM) lymphoblasts and/or extramedullary disease after 4-6 weeks of induction chemotherapy. Disease features and clinical outcomes were reported in 325 of 6,167 (5%) patients age 21 years and younger treated in 14 cooperative study groups between 2000 and 2018.
RESULTS
With a median follow-up period of 6.4 years (range, 0.3-17.9 years), the 10-year overall survival (OS) was 54.7% (SE = 2.9), which is significantly higher than the 27.6% (SE = 2.9) observed in the historical cohort …
Total citations
20242
Scholar articles
EA Raetz, P Rebora, V Conter, M Schrappe, M Devidas… - Journal of Clinical Oncology, 2023